8-K: Biora Therapeutics Completes BT-600 Trial, Reports Q1 2024 Financials and Secures $31 Million in Capital

Biora Therapeutics announced the completion of its BT-600 clinical trial, progress in its BioJet platform partnering, and first quarter 2024 financial results, including a net loss of $4.2 million.

Summary

• Biora Therapeutics has completed dosing in its clinical trial for BT-600, with results expected in late June 2024.
• The company is progressing its BioJet platform and is actively seeking a partner, aiming to confirm interest by mid-2024.
• First quarter 2024 operating expenses were $16.1 million, including $1.5 million in non-cash stock-based compensation.
• The net loss for the first quarter of 2024 was $4.2 million, or $0.14 per share, which includes a $13.9 million gain on warrant liabilities.
• Biora raised $31 million in capital over the past four months, including $19.8 million from note exchanges, $3 million from asset monetization, $2.9 million from equity proceeds, and a $6 million registered direct placement.
• The company's NaviCap device showed successful drug delivery in the colon, with plasma levels of tofacitinib approximately 3-4 times lower than conventional oral doses.
• BioJet platform studies demonstrated over 15% bioavailability compared to IV administration for peptide and antibody candidates.

Sentiment

Score: 7

Explanation: The document presents a generally positive outlook with successful clinical trial completion, promising technology advancements, and significant capital raising. However, the net loss and ongoing operating expenses temper the overall sentiment.

Positives

• The NaviCap device showed successful drug delivery to the colon, with lower plasma levels of tofacitinib compared to conventional oral doses, potentially reducing toxicity.
• The BioJet platform continues to show progress, exceeding its performance target of 15% bioavailability compared to IV administration.
• Biora secured $31 million in capital over the past four months, strengthening its financial position.
• The company has reduced notes outstanding by more than $80 million over the last three quarters.
• The company is actively seeking a partner for the BioJet platform, with strong interest from both current collaborators and new companies.

Negatives

• The company reported a net loss of $4.2 million for the first quarter of 2024.
• Operating expenses were $16.1 million for the first quarter of 2024, which is higher than the $13.3 million in the previous quarter and $15.5 million in the same quarter of the previous year.

Risks

• The company's ability to achieve its business objectives depends on raising sufficient capital.
• There is a risk that clinical trial results may not meet expectations.
• The company's ability to secure a partner for the BioJet platform is not guaranteed.
• The company's financial results are subject to fluctuations due to changes in the fair value of warrant liabilities.

Future Outlook

Biora expects to receive final SAD/MAD data during Q2 2024 and plans to present topline data from the clinical trial toward the end of the second quarter. The company anticipates initiating a clinical study in active ulcerative colitis patients during the second half of 2024 and is on track toward a pharma partnership for the BioJet platform in 2024.

Management Comments

• Adi Mohanty, Chief Executive Officer of Biora Therapeutics, stated that they were gratified to see the excellent interim results from the BT-600 clinical trial.
• Mr. Mohanty also mentioned that everything they have seen so far reinforces their belief that the NaviCap platform could optimize JAK inhibitor therapy in ulcerative colitis.
• Mr. Mohanty noted that they are encouraged by the engagement shown by some of their current collaborators and are also seeing strong interest from new companies for the BioJet platform.

Industry Context

Biora's focus on targeted oral delivery aligns with the broader industry trend of developing more patient-friendly and effective drug delivery methods. The company's work on ulcerative colitis and systemic oral delivery of biologics addresses significant unmet needs in the pharmaceutical market.

Comparison to Industry Standards

• The reported plasma levels of tofacitinib being 3-4 times lower than conventional oral doses with the NaviCap device suggests a potential advantage in terms of reduced systemic exposure and toxicity compared to standard oral formulations, which is a key focus in the development of new therapies for ulcerative colitis.
• The BioJet platform's achievement of over 15% bioavailability compared to IV administration is a significant milestone, as oral delivery of large molecules like peptides and antibodies has historically been challenging. This result positions Biora favorably against companies working on similar oral delivery technologies, such as Rani Therapeutics and Entera Bio, which are also developing oral delivery platforms for biologics.
• The company's ability to raise $31 million in capital over the past four months demonstrates investor confidence in its technology and strategy, which is a positive sign compared to other biotech companies that may struggle to secure funding in the current market environment.

Stakeholder Impact

• Shareholders may be encouraged by the positive clinical trial results and capital raising.
• Employees may be motivated by the company's progress and future prospects.
• Patients with ulcerative colitis may benefit from the potential of the NaviCap platform.
• Potential partners may be interested in the BioJet platform's progress.

Next Steps

• Biora expects to receive final SAD/MAD data during Q2 2024.
• The company plans to present topline data from the BT-600 clinical trial toward the end of the second quarter.
• Biora will present clinical data on the function of the NaviCap device at the DDW conference on May 19, 2024.
• The company anticipates initiating a clinical study in active ulcerative colitis patients during the second half of 2024.
• Biora will share an update on data from recent animal studies at the Next Gen Peptide Formulation & Delivery Summit in June 2024.
• The company is working towards a pharma partnership for the BioJet platform in 2024.

Key Dates

Keywords

Biora Therapeutics, NaviCap, BioJet, BT-600, Ulcerative Colitis, Tofacitinib, Oral Delivery, Clinical Trial, Pharmacokinetics, Bioavailability, Capital Raise, Financial Results